These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Chen H; Sun Y; Wu C; Magyar CE; Li X; Cheng L; Yao JL; Shen S; Osunkoya AO; Liang C; Huang J Endocr Relat Cancer; 2012 Jun; 19(3):321-31. PubMed ID: 22389383 [TBL] [Abstract][Full Text] [Related]
4. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Liu Q; Russell MR; Shahriari K; Jernigan DL; Lioni MI; Garcia FU; Fatatis A Cancer Res; 2013 Jun; 73(11):3297-305. PubMed ID: 23536554 [TBL] [Abstract][Full Text] [Related]
5. [Neuroendocrine differentiation in prostate cancer]. Wu CY; Na YQ; Yao JL; di Sant'Agnese PA; Huang JT Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):565-7. PubMed ID: 17134555 [No Abstract] [Full Text] [Related]
6. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. Ku SY; Wang Y; Garcia MM; Yamada Y; Mizuno K; Long MD; Rosario S; Chinnam M; Al Assaad M; Puca L; Kim MJ; Bakht MK; Venkadakrishnan VB; Robinson BD; Acosta AM; Wadosky KM; Mosquera JM; Goodrich DW; Beltran H J Clin Invest; 2024 Jul; 134(17):. PubMed ID: 39024561 [TBL] [Abstract][Full Text] [Related]
7. The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer. Cheng S; Prieto-Dominguez N; Yang S; Connelly ZM; StPierre S; Rushing B; Watkins A; Shi L; Lakey M; Baiamonte LB; Fazili T; Lurie A; Corey E; Shi R; Yeh Y; Yu X Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):661-669. PubMed ID: 32313141 [TBL] [Abstract][Full Text] [Related]
8. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615 [TBL] [Abstract][Full Text] [Related]
9. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. Lapuk AV; Wu C; Wyatt AW; McPherson A; McConeghy BJ; Brahmbhatt S; Mo F; Zoubeidi A; Anderson S; Bell RH; Haegert A; Shukin R; Wang Y; Fazli L; Hurtado-Coll A; Jones EC; Hach F; Hormozdiari F; Hajirasouliha I; Boutros PC; Bristow RG; Zhao Y; Marra MA; Fanjul A; Maher CA; Chinnaiyan AM; Rubin MA; Beltran H; Sahinalp SC; Gleave ME; Volik SV; Collins CC J Pathol; 2012 Jul; 227(3):286-97. PubMed ID: 22553170 [TBL] [Abstract][Full Text] [Related]
10. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Huang J; Yao JL; Zhang L; Bourne PA; Quinn AM; di Sant'Agnese PA; Reeder JE Am J Pathol; 2005 Jun; 166(6):1807-15. PubMed ID: 15920165 [TBL] [Abstract][Full Text] [Related]
11. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells. Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967 [TBL] [Abstract][Full Text] [Related]
13. A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer. Ippolito JE; Piwnica-Worms D PLoS One; 2014; 9(2):e88667. PubMed ID: 24551133 [TBL] [Abstract][Full Text] [Related]
14. Do neuroendocrine cells come up large in small cell lung cancer? Goldstein AS; Huang J Cell Cycle; 2011 Nov; 10(21):3627. PubMed ID: 22024918 [No Abstract] [Full Text] [Related]
15. Neuroendocrine cells: potential cells of origin for small cell lung carcinoma. Cheng CY; Nikitin AY Cell Cycle; 2011 Nov; 10(21):3629-30. PubMed ID: 22024916 [No Abstract] [Full Text] [Related]
16. Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma. Xiao GQ; Ho G; Suen C; Hurth KM Prostate; 2021 Jun; 81(8):469-477. PubMed ID: 33848377 [TBL] [Abstract][Full Text] [Related]
17. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations. Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261 [TBL] [Abstract][Full Text] [Related]
18. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma. Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201 [TBL] [Abstract][Full Text] [Related]